Gene-editing platform for genetic disorders like Duchenne Muscular Dystrophy

Standardized gene-editing and delivery platform for genetic disorders: a CRISPR/Cas9 gene-editing therapy for Duchenne Muscular Dystrophy (STAGENE)

NTrans, in collaboration with LUMC, has embarked on a pioneering STAGENE project. This venture aims to harness the potential of the groundbreaking CRISPR/Cas9 gene editing technology to offer new treatments for Duchenne Muscular Dystrophy (DMD). This newly established public-private partnership marks a hopeful stride toward addressing genetic disorders at their root.

Duchenne Muscular Dystrophy affects approximately 1 in every 5,000 live male births. Over 10,000 in the US and 25,000 in the EU suffer from this debilitating condition. Patients with DMD experience muscle weakening, leading to significant loss of functionality and independence, often confining them to wheelchairs in their youth. The societal and economic toll of DMD is immense, underscoring the urgency for innovative solutions.

The STAGENE project offers hope through a cutting-edge approach. By editing the very genes that cause DMD, the project aims to halt or even reverse the progression of the disease. Unlike traditional treatments that merely manage symptoms, gene editing can address the disease's root cause. The therapy being developed focuses on maintaining the upper limb mobility of DMD patients, a critical factor in preserving their independence and quality of life.

The culmination of this project will see the development and initial clinical trials of gene therapy. It's hoped that this treatment will serve as a beacon of hope for those living with DMD, offering them a chance at improved mobility, independence, and a better quality of life. Although still in its developmental phase, the promising strides made by NTrans and LUMC could usher in a new era of genetic therapies for a host of conditions.

NTrans and LUMC have teamed up to pioneer a transformative approach to treat Duchenne Muscular Dystrophy using cutting-edge gene editing technology with a unique non-viral delivery platform. This venture aims to enhance mobility and life quality for patients, signaling a potential revolution in genetic disorder treatments.
Technology Readiness Level (TRL)
4 - 5
Time period
24 months